ArticleThe pharmacogenomics journal2016
Cost-effectiveness of one-time genetic testing to minimize lifetime adverse drug reactions.
Article in The pharmacogenomics journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Economic evaluation in psychiatric pharmacogenomics: a systematic review.The pharmacogenomics journal · 2021Pooled it
- Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder.Psychopharmacology · 2017Pooled it
- Cost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in Germany.Advances in therapy · 2016Pooled it
- Trial
- Benchmark of Open-Access Star-Allele Callers to Accurately Assess Haplotypes and Phenotypes in Pharmacogenetic Studies.Clinical pharmacology and therapeutics · 2026Article
- Improving prescribing: a feasibility study of pharmacogenetic testing with clinical decision support in primary healthcare in Singapore.Family practice · 2024Article
- Haplotype phasing of CYP2D6: an allelic ratio method using Agena MassARRAY data.Translational psychiatry · 2024Article
- Evaluation of Potential Drug Interactions with AiDKlinikIntegrated pharmacy research & practice · 2022Article
- Genome-wide Study Identifies Association between HLA-BAmerican journal of human genetics · 2020Article
- Pharmacogenomics of Antidepressant and Antipsychotic Treatment: How Far Have We Got and Where Are We Going?Frontiers in psychiatry · 2020Review
- Cost-effectiveness of precision medicine: a scoping review.International journal of public health · 2019Article
- Development of the PGx-Passport: A Panel of Actionable Germline Genetic Variants for Pre-Emptive Pharmacogenetic Testing.Clinical pharmacology and therapeutics · 2019Article
- Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults.The pharmacogenomics journal · 2019Article
- Article
- Pharmacogenomic potential in advanced cancer patients.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2019Observational
- Use of Pharmacogenetic Drugs by the Dutch Population.Frontiers in genetics · 2019Article
- On the readiness of physicians for pharmacogenomics testing: an empirical assessment.The pharmacogenomics journal · 2018Article
- Cost-effectiveness of cytochrome P450 2C19 *2 genotype-guided selection of clopidogrel or ticagrelor in Chinese patients with acute coronary syndrome.The pharmacogenomics journal · 2018Article
- Personalized medicines - are pharmacists ready for the challenge?Integrated pharmacy research & practice · 2018Review
- Prioritising the application of genomic medicine.NPJ genomic medicine · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We evaluated the cost-effectiveness of one-time pharmacogenomic testing for preventing adverse drug reactions (ADRs) over a patient's lifetime. We developed a Markov-based Monte Carlo microsimulation model to represent the ADR events in the lifetime of each patient. The base-case considered a 40-year-old patient. We measured health outcomes in life years (LYs) and quality-adjusted LYs (QALYs) and estimated costs using 2013 US$. In the base-case, one-time genetic testing had an incremental cost-effectiveness ratio (ICER) of $43,165 (95% confidence interval (CI) is ($42,769,$43,561)) per additional LY and $53,680 per additional QALY (95% CI is ($53,182,$54,179)), hence under the base-case one-time genetic testing is cost-effective. The ICER values were most sensitive to the average probability of death due to ADR, reduction in ADR rate due to genetic testing, mean ADR rate and cost of genetic testing.
Indexed as
Identifiers
25987241What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.